首页> 外文期刊>Materials science & engineering, C. Materials for Biogical applications >Controlled release of monoclonal antibodies from poly-L-lysine-coated alginate spheres within a scaffolded implant mitigates autoimmune responses to transplanted islets and limits systemic antibody toxicity
【24h】

Controlled release of monoclonal antibodies from poly-L-lysine-coated alginate spheres within a scaffolded implant mitigates autoimmune responses to transplanted islets and limits systemic antibody toxicity

机译:来自聚-L-赖氨酸涂层的藻酸盐球体的单克隆抗体的单克隆抗体的控制释放减轻了对移植的胰岛的自身免疫反应,并限制了全身抗体毒性

获取原文
获取原文并翻译 | 示例
       

摘要

Immunomodulatory monoclonal antibodies (IM-mAbs) are a cornerstone of modern immunotherapy; however, when administered systemically (i.e., via injection), these agents can generate a variety of negative side effects. For many diseases, systemic delivery of IM-mAbs is the most effective mode of treatment, but in instances where the cellular target occupies a limited, well-defined space (e.g., solid tumors or cellularized implants) local, controlled release of IM-mAbs might be desirable. Antibodies are highly sensitive to a variety of environmental conditions, which limit the kinds of polymers suitable for antibody retention and controlled release. The present study evaluates the release of antibodies from biocompatible, 2-mm diameter alginate spheres coated with poly-L-lysine and a thin outer layer of alginate (APA spheres). In vitro, rates of antibody release (including IM-mAbs) could be incrementally decreased and made linear by incrementally increasing the quantity of poly-L-lysine deposited on the alginate, with linear release lasting in one scenario for at least 46 days. To evaluate the bioactivity in vivo of IM-mAbs, APA spheres loaded with either anti-CD3 epsilon or anti-CD95 mAb were incorporated into scaffolded islet implant (SI) test-beds and the SIs implanted into a mouse model of autoimmune (type 1) diabetes. Release of mAbs within the implanted SIs resulted in reduced autoimmune responses to both transplanted and native islets. Notably, mice implanted with APA spheres loaded with quantities of anti-CD95 mAb that would be lethal if given systemically showed immunomodulation with no toxic side effects. Collectively, our results indicate that APA spheres are a relatively simple means to evaluate the effects of local, controlled release of IM-mAbs in a way that preserves mAb function and limits systemic toxicity.
机译:免疫调节单克隆抗体(IM-MAB)是现代免疫疗法的基石;然而,当系统性上(即,通过注射)给药时,这些试剂可以产生各种负副作用。对于许多疾病,IM-MAb的全身递送是最有效的治疗方式,但在细胞目标占据有限的,明确的空间(例如,实体肿瘤或细胞化植入物)的情况下,IM-MAb的局部释放可能是可取的。抗体对各种环境条件非常敏感,这限制了适用于抗体保留和控制释放的聚合物种类。本研究评估涂覆有聚-L-赖氨酸的生物相容性,2mm直径的藻酸盐球的抗体的释放和藻酸盐(APA球体)的薄外层。体外,抗体释放速率(包括IM-MAb)可以通过逐步增加沉积在藻酸盐上沉积在藻酸盐上的聚-L-赖氨酸的量,在一种情况下持续到至少46天的线性释放。为了评估IM-MAB体内的生物活性,用抗CD3ε或抗CD95 mAb掺入抗CD3ε或抗CD95mab的APA球体掺入支架胰岛植入物(Si)试验床中,SIS注入到自身免疫小鼠模型中(1型) 糖尿病。在植入的SIS内释放mAb,导致对移植和本地胰岛的自身免疫反应减少。值得注意的是,如果在系统性地显示免疫调节的免疫调节,则植入含有抗CD95mAb的量的APA球体的小鼠将是致命的。统称,我们的结果表明APA球体是评估局部控制释放的效果的一种相对简单的方法,以防止MAB函数并限制全身毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号